Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.89 [0.79, 1.00] | | < 1 | | 25% | 3 studies (3/-) | 97.7 % | some concern | not evaluable | moderate | crucial | - |
deaths (OS) (extension) | 0.82 [0.71, 0.94] | | < 1 | | 0% | 1 study (1/-) | 99.7 % | NA | not evaluable | | important | - |
progression or deaths (PFS) | 0.83 [0.72, 0.96] | | < 1 | | 0% | 2 studies (2/-) | 99.4 % | some concern | not evaluable | moderate | important | - |
CRR | 1.96 [1.21, 3.17] | | > 1 | | 0% | 1 study (1/-) | 99.7 % | NA | not evaluable | | non important | - |
DOR | 0.30 [0.11, 0.78] | | < 1 | | 88% | 3 studies (3/-) | 99.3 % | some concern | not evaluable | moderate | non important | - |
objective responses (ORR) | 0.76 [0.38, 1.53] | | > 1 | | 93% | 3 studies (3/-) | 22.1 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
AE (any grade) | 0.43 [0.11, 1.58] | | < 1 | | 74% | 3 studies (3/-) | 89.9 % | some concern | not evaluable | moderate | non important | - |
AE (grade 3-4) | 0.45 [0.13, 1.54] | | < 1 | | 98% | 3 studies (3/-) | 89.9 % | some concern | not evaluable | moderate | non important | - |
AE leading to death (grade 5) | 1.25 [0.88, 1.79] | | < 1 | | 0% | 3 studies (3/-) | 10.6 % | some concern | not evaluable | moderate | non important | - |
AE leading to treatment discontinuation (any grade) | 0.38 [0.11, 1.27] | | < 1 | | 97% | 3 studies (3/-) | 94.2 % | some concern | not evaluable | moderate | non important | - |
SAE (any grade) | 0.93 [0.77, 1.13] | | < 1 | | 34% | 3 studies (3/-) | 75.9 % | some concern | not evaluable | moderate | non important | - |
STRAE (any grade) | 0.68 [0.33, 1.38] | | < 1 | | 92% | 3 studies (3/-) | 85.8 % | some concern | not evaluable | moderate | non important | - |
TRAE (any grade) | 0.27 [0.07, 1.00] | | < 1 | | 95% | 3 studies (3/-) | 97.5 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) | 0.24 [0.05, 1.31] | | < 1 | | 99% | 3 studies (3/-) | 94.9 % | some concern | not evaluable | moderate | non important | - |
TRAE leading to death (grade 5) | 0.89 [0.35, 2.26] | | < 1 | | 38% | 3 studies (3/-) | 59.9 % | some concern | not evaluable | moderate | non important | - |
TRAE leading to discontinuation (any grade) | 0.22 [0.12, 0.38] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
Anaemia TRAE (grade 3-4) | 0.37 [0.10, 1.37] | | < 1 | | 86% | 3 studies (3/-) | 93.1 % | some concern | not evaluable | moderate | non important | - |
Asthenia TRAE (grade 3-4) | 0.81 [0.30, 2.24] | | < 1 | | 69% | 3 studies (3/-) | 65.4 % | some concern | not evaluable | moderate | non important | - |
Constipation TRAE (grade 3-4) | 0.02 [0.00, 0.38] | | < 1 | | 0% | 1 study (1/-) | 99.5 % | NA | not evaluable | | non important | - |
Decreased appetite TRAE (grade 3-4) | 2.41 [0.46, 12.52] | | < 1 | | 0% | 2 studies (2/-) | 14.9 % | some concern | not evaluable | moderate | non important | - |
Fatigue TRAE (grade 3-4) | 0.84 [0.23, 3.04] | | < 1 | | 66% | 3 studies (3/-) | 60.4 % | some concern | not evaluable | moderate | non important | - |
Febrile neutropenia TRAE (grade 3-4) | 0.04 [0.00, 0.27] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
Nausea TRAE (grade 3-4) | 1.11 [0.24, 5.19] | | < 1 | | 4% | 2 studies (2/-) | 44.8 % | some concern | not evaluable | moderate | non important | - |
Neutropenia TRAE (grade 3-4) | 0.15 [0.01, 3.89] | | < 1 | | 94% | 3 studies (3/-) | 87.1 % | some concern | not evaluable | moderate | non important | - |
Peripheral neuropathy TRAE (grade 3-4) | 0.12 [0.01, 0.95] | | < 1 | | 0% | 1 study (1/-) | 97.7 % | NA | not evaluable | | non important | - |
Pruritus TRAE (grade 3-4) | 1.42 [0.11, 18.55] | | < 1 | | 0% | 2 studies (2/-) | 39.5 % | some concern | not evaluable | moderate | non important | - |
Rash TRAE (grade 3-4) | 2.36 [0.21, 26.86] | | < 1 | | 0% | 2 studies (2/-) | 24.7 % | some concern | not evaluable | moderate | non important | - |
Thrombocytopenia TRAE (grade 3-4) | 0.35 [0.03, 4.69] | | < 1 | | 83% | 2 studies (2/-) | 78.5 % | some concern | not evaluable | moderate | non important | - |
AE (grade 3-4) endpoints 00 |
Anaemia AE (grade 3-4) | 0.29 [0.02, 3.86] | | < 1 | | 99% | 2 studies (2/-) | 82.3 % | some concern | not evaluable | moderate | non important | - |
Asthenia AE (grade 3-4) | 0.88 [0.32, 2.41] | | < 1 | | 78% | 2 studies (2/-) | 59.5 % | some concern | not evaluable | moderate | non important | - |
Fatigue AE (grade 3-4) | 0.41 [0.14, 1.17] | | < 1 | | 75% | 2 studies (2/-) | 95.2 % | some concern | not evaluable | moderate | non important | - |
Febrile neutropenia AE (grade 3-4) | 0.41 [0.01, 11.84] | | < 1 | | 81% | 2 studies (2/-) | 69.7 % | some concern | not evaluable | moderate | non important | - |
Hypertension AE (grade 3-4) | 1.16 [0.29, 4.59] | | < 1 | | 77% | 2 studies (2/-) | 41.4 % | some concern | not evaluable | moderate | non important | - |
Leucopenia AE (grade 3-4) | 0.14 [0.00, 5.94] | | < 1 | | 86% | 2 studies (2/-) | 84.5 % | some concern | not evaluable | moderate | non important | - |
Nausea AE (grade 3-4) | 0.26 [0.04, 1.67] | | < 1 | | 67% | 2 studies (2/-) | 92.2 % | some concern | not evaluable | moderate | non important | - |
Neutropenia AE (grade 3-4) | 0.08 [0.00, 29.10] | | < 1 | | 94% | 2 studies (2/-) | 79.0 % | some concern | not evaluable | moderate | non important | - |
Thrombocytopenia AE (grade 3-4) | 0.14 [0.00, 12.34] | | < 1 | | 95% | 2 studies (2/-) | 79.8 % | some concern | not evaluable | moderate | non important | - |
Vomiting AE (grade 3-4) | 0.36 [0.04, 2.88] | | < 1 | | 73% | 2 studies (2/-) | 83.2 % | some concern | not evaluable | moderate | non important | - |